Zhou X D
Liver Cancer Institute, Shanghai Medical University.
Zhonghua Zhong Liu Za Zhi. 1992 Jan;14(1):61-3.
Cryosurgery with liquid nitrogen was employed in treating 70 patients with primary liver cancer (PLC). There were 25 cases with small PLC (less than or equal to 5 cm). The postoperative course was uneventful in all. The 1-5 year survival rates were 59.1% (39/66), 37.5% (24/64), 27.0% (17/63), 17.5% (10/57), 12.5% (7/56), respectively in the whole series. The 1-5 year survival rates were 48.4% (15/31), 16.1% (5/31), 6.5% (2/31), 6.5% (2/31), 3.2% (1/31) for 31 cases treated 1973-1977, and 68.6% (24/35), 57.6% (19/33), 46.9% (15/32), 30.8% (8/26), 24.0% (6/25) for 39 cases treated 1978-1989. It is suggested that hepatic cryosurgery is a promising and safe treatment for non-resectable PLC. The remarkable improvement in survival in the latter time period might be attributed to the increased incidence of small PLC, the combined use of hepatic artery ligation and/or regional chemotherapy by hepatic artery cannulation and multimodality treatment.
采用液氮冷冻手术治疗70例原发性肝癌(PLC)患者。其中小肝癌(直径小于或等于5cm)25例。所有患者术后过程均顺利。全组患者1至5年生存率分别为59.1%(39/66)、37.5%(24/64)、27.0%(17/63)、17.5%(10/57)、12.5%(7/56)。1973年至1977年治疗的31例患者,1至5年生存率分别为48.4%(15/31)、16.1%(5/31)、6.5%(2/31)、6.5%(2/31)、3.2%(1/31);1978年至1989年治疗的39例患者,1至5年生存率分别为68.6%(24/35)、57.6%(19/33)、46.9%(15/32)、30.8%(8/26)、24.0%(6/25)。提示肝冷冻手术是一种有前途且安全的不可切除性PLC治疗方法。后期生存率的显著提高可能归因于小肝癌发病率的增加、肝动脉结扎和/或经肝动脉插管区域化疗的联合应用以及多模式治疗。